WID’s Randolph Ashton, assistant professor of biomedical engineering, is the new associate director for UW–Madison’s Stem Cell and Regenerative Medicine Center.
The Wisconsin State Journal, as part of its feature highlighting stem cell research at UW 20 years after James Thomson’s discovery, highlights WID researchers Randolph Ashton and Kris Saha.
A paper published in eLife this week by an interdisciplinary team at WID describes new methods for reproducibly manufacturing brain and spinal cord organoids with strict control over morphogenic and developmental processes.
UW researchers led by WID’s Kris Saha join the National Institutes of Health’s Somatic Cell Genome Editing Consortium with a major collaborative award.
A team of researchers is developing a new approach for maintaining open blood vessels in the wake of surgeries such as angioplasties or bypasses.
Investigators from WID are among the recipients of the latest round of UW2020 awards.
The scholarship recognizes promising undergraduates who plan to pursue a PhD or MD/PhD followed by a research career in engineering, mathematics, or the natural sciences.
Biomedical engineering professor and Discovery Fellow Kristyn Masters and colleagues identified the early stages of a process that may eventually cause aortic stenosis, a severe narrowing of the aortic valve that reduces blood flow to the body and weakens the heart.
In August 2017, Randolph Ashton received almost $800,000 from the National Institute of Neurological Disorders and Stroke, part of NIH, to continue a five-year research study of Lou Gehrig’s disease (amyotrophic lateral sclerosis, or ALS), after successfully completing its first phase.
The National Science Foundation has awarded nearly $20 million to a consortium of universities to support a new engineering research center that will develop transformative tools and technologies for the consistent, scalable, and low-cost production of high-quality living therapeutic cells. Several WID investigators are collaborators on the project.
The main scientific focus of the lab is in defining how the epigenome controls cell identity. We want to know how non-genetic information controls functional specialization of a cell and use this knowledge to direct efficient conversion of desired cell types with the ultimate goal of improving stem cell based therapy.
By bringing together stem cell biology, genome engineering, and biomaterials expertise, the Saha lab generates new tools for use with human-induced pluripotent stem cells to ask unique questions about human biology and disease.
The Turng lab works with injection molding and innovative plastics manufacturing processes (such as microcellular injection molding / MuCell process), pioneering materials (biobased polymers, nanocomposites, electro-active polymers (EAPs), etc.), and intelligent modeling and process control (computer-aided engineering (CAE), numerical simulation, design and process optimization, intelligent injection molding control, and Internet-based collaboration) to advance the science and manufacturing techniques surrounding tissue engineering scaffolds.
The Ashton Group is working to understand, model, and recapitulate in vitro the instructive signals utilized by human embryos to pattern tissue-specific differentiation of pluripotent stem cells, and apply this knowledge towards the rational design of tissue engineered scaffolds and other regenerative therapeutic strategies.